Supernus Pharmaceuticals (NASDAQ:SUPN) lost ~20% in the premarket on Wednesday after the neuro-focused biopharma said its ...

A digital-based therapy using a mobile application with recording and analytic functions can relieve symptoms of insomnia and ...

Craske and her colleagues hypothesized that targeting this mechanism for reward sensitivity could help strengthen affected ...

In today's Therapy Thursday, therapist Kyann Mitchner with Sunbeam Family Services discusses the physical impact stress, ...

Supernus Pharmaceuticals said on Tuesday its depression treatment trial failed to meet the main goal of reduction in depressive symptoms, sending its shares down 22% aftermarket.

“This bill would require the Alabama Medicaid Agency to cover screening and would also regulate how Medicaid covers prescription drugs used to treat postpartum depression,” the legislation states.

Depression doesn't just affect mood — it changes how people eat. Some lose their appetite, while others crave food, ...

Study looked into digital cognitive behavioural therapy for insomnia among young people in first such clinical research in Asia.

Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further ...

Seeking mental health help is a significant step, but that first intake session can often feel more like paperwork than ...

New postpartum depression findings could lead to a blood test to identify women at risk and possibly even to a preventive treatment.

After SPN-820's failure, Supernus is relying on its non-stimulant ADHD drug Qelbree and the recently approved Parkinson’s ...